Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies-Reference-Cited by-同舟云学术

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies

Published:2021-12-18 Issue: Volume: Page:
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Melvold Katrine¹²,Giliberto Mariaserena¹²³,Karlsen Linda¹²³,Ayuda‐Durán Pilar⁴⁵^ORCID,Hanes Robert⁴⁵,Holien Toril⁶⁷⁸^ORCID,Enserink Jorrit⁴⁵⁹,Brown Jennifer R.¹⁰¹¹,Tjønnfjord Geir E.²³¹²,Taskén Kjetil¹²³^ORCID,Skånland Sigrid S.¹²^ORCID

Affiliation:

1. Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Norway

2. K. G. Jebsen Centre for B Cell Malignancies Institute of Clinical Medicine University of Oslo Norway

3. Institute of Clinical Medicine University of Oslo Norway

4. Faculty of Medicine Centre for Cancer Cell Reprogramming Institute of Clinical Medicine University of Oslo Norway

5. Department of Molecular Cell Biology Institute for Cancer Research Oslo University Hospital Norway

6. Department of Clinical and Molecular Medicine NTNU – Norwegian University of Science and Technology Trondheim Norway

7. Department of Immunology and Transfusion Medicine St. Olav’s University Hospital Trondheim Norway

8. Department of Hematology St. Olav’s University Hospital Trondheim Norway

9. Faculty of Mathematics and Natural Sciences Department of Biosciences University of Oslo Norway

10. Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA

11. Harvard Medical School Boston MA USA

12. Department of Haematology Oslo University Hospital Norway

Funder

Stiftelsen Kristian Gerhard Jebsen

Centre for Digital Life Norway

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13153

Reference48 articles.

1. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia

2. Multiple Myeloma: Available Therapies and Causes of Drug Resistance

3. Management of Drug Resistance in Mantle Cell Lymphoma

4. B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia

5. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Standardized assays to monitor drug sensitivity in hematologic cancers;Cell Death Discovery;2023-12-01

2. A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine;Cell Death Discovery;2023-04-13

3. Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines;Frontiers in Oncology;2022-11-29

4. Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models;Trends in Pharmacological Sciences;2022-11

5. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia;Clinical Cancer Research;2022-08-23